[L02BA01, tamoxifen, The risk or severity of cardiotoxicity can be increased when Tamoxifen is combined with Paclitaxel poliglumex.]
[L01CB02, teniposide, The risk or severity of cardiotoxicity can be increased when Teniposide is combined with Paclitaxel poliglumex.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Paclitaxel poliglumex.]
[L01XF01, tretinoin, The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Paclitaxel poliglumex.]
[L01CA01, vinblastine, The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Paclitaxel poliglumex.]
[L01CA02, vincristine, The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Paclitaxel poliglumex.]
[L01CA03, vindesine, The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Paclitaxel poliglumex.]
[L03AB11, peginterferon alfa-2a, The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Paclitaxel poliglumex.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Paclitaxel poliglumex.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Pertuzumab is combined with Paclitaxel poliglumex.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Benzocaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Benzyl alcohol.]
[L01DC01, bleomycin, The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel poliglumex.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel poliglumex.]
[L01XX27, arsenic trioxide, The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Oxybuprocaine.]
[L01BC06, capecitabine, The risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel poliglumex.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Capsaicin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Chloroprocaine.]
[L01AD01, carmustine, The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Paclitaxel poliglumex.]
[L01FD01, trastuzumab, The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel poliglumex.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Dyclonine.]
[L01BB05, fludarabine, The risk or severity of cardiotoxicity can be increased when Fludarabine is combined with Paclitaxel poliglumex.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.]
[L01XA01, cisplatin, The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Paclitaxel poliglumex.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Levobupivacaine.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Cocaine.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[L01EA01, imatinib, The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Paclitaxel poliglumex.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel poliglumex.]
[L01AA01, cyclophosphamide, The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Paclitaxel poliglumex.]
[L01DB02, daunorubicin, The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Paclitaxel poliglumex.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Cinchocaine.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Pramocaine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Diphenhydramine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ropivacaine.]
[L01XG01, bortezomib, The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel poliglumex.]
[L01DB01, doxorubicin, The risk or severity of cardiotoxicity can be increased when Doxorubicin is combined with Paclitaxel poliglumex.]
[L01CA04, vinorelbine, The risk or severity of cardiotoxicity can be increased when Vinorelbine is combined with Paclitaxel poliglumex.]
[L01DB03, epirubicin, The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Paclitaxel poliglumex.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Paclitaxel poliglumex.]
[L04AA40, cladribine, The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Paclitaxel poliglumex.]
[L01BC02, fluorouracil, The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Paclitaxel poliglumex.]
[L01DB06, idarubicin, The risk or severity of cardiotoxicity can be increased when Idarubicin is combined with Paclitaxel poliglumex.]
[L01AA06, ifosfamide, The risk or severity of cardiotoxicity can be increased when Ifosfamide is combined with Paclitaxel poliglumex.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Paclitaxel poliglumex.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Articaine.]
[L01DC03, mitomycin, The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Paclitaxel poliglumex.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Lidocaine.]
[L01AA05, mechlorethamine, The risk or severity of cardiotoxicity can be increased when Mechlorethamine is combined with Paclitaxel poliglumex.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Mepivacaine.]
[L04AX03, methotrexate, The risk or severity of cardiotoxicity can be increased when Methotrexate is combined with Paclitaxel poliglumex.]
[L01DB07, mitoxantrone, The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Paclitaxel poliglumex.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel poliglumex.]
[L01CD02, docetaxel, The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Paclitaxel poliglumex.]
[L01XX01, amsacrine, The risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[L01XX08, pentostatin, The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Paclitaxel poliglumex.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Procaine.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[L01CD04, cabazitaxel, The risk or severity of cardiotoxicity can be increased when Cabazitaxel is combined with Paclitaxel poliglumex.]
[S02DA03, antipyrine, The metabolism of Paclitaxel can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Paclitaxel.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Paclitaxel.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paclitaxel.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Paclitaxel.]
[L04AA27, fingolimod, Paclitaxel may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, Succinylcholine may increase the neurotoxic activities of Paclitaxel.]
[J01EC02, sulfadiazine, The metabolism of Paclitaxel can be decreased when combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Paclitaxel.]
[M04AB02, sulfinpyrazone, The metabolism of Paclitaxel can be increased when combined with Sulfinpyrazone.]
[N05AL01, sulpiride, Sulpiride may increase the neurotoxic activities of Paclitaxel.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Paclitaxel.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Paclitaxel.]
[L02BA01, tamoxifen, The metabolism of Paclitaxel can be increased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Paclitaxel.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Paclitaxel.]
[G03BA03, testosterone, The metabolism of Paclitaxel can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Paclitaxel can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Paclitaxel may increase the neurotoxic activities of Lurasidone.]
[N04BC07, apomorphine, The metabolism of Paclitaxel can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Paclitaxel.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Paclitaxel.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the neurotoxic activities of Paclitaxel.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Paclitaxel.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Paclitaxel.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Paclitaxel.]
[N05AB08, thioproperazine, Paclitaxel may increase the neurotoxic activities of Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Paclitaxel.]
[N05AF04, thiothixene, Paclitaxel may increase the neurotoxic activities of Thiothixene.]
[N05AL03, tiapride, Paclitaxel may increase the neurotoxic activities of Tiapride.]
[B01AC05, ticlopidine, The metabolism of Paclitaxel can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Paclitaxel.]
[P01AB02, tinidazole, Paclitaxel may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Paclitaxel.]
[V04CA01, tolbutamide, The metabolism of Paclitaxel can be decreased when combined with Tolbutamide.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Paclitaxel.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Paclitaxel.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Paclitaxel.]
[N06AX05, trazodone, The metabolism of Paclitaxel can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Paclitaxel can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Paclitaxel can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Paclitaxel.]
[N05CD05, triazolam, The metabolism of Paclitaxel can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Paclitaxel.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the neurotoxic activities of Paclitaxel.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Paclitaxel.]
[N05AD02, trifluperidol, Paclitaxel may increase the neurotoxic activities of Trifluperidol.]
[N05AA05, triflupromazine, Triflupromazine may increase the neurotoxic activities of Paclitaxel.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Paclitaxel can be increased when combined with Mometasone.]
[R06AD01, trimeprazine, Paclitaxel may increase the neurotoxic activities of Alimemazine.]
[N03AC02, trimethadione, The metabolism of Paclitaxel can be decreased when combined with Trimethadione.]
[C02BA01, trimethaphan, Paclitaxel may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Paclitaxel can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may increase the neurotoxic activities of Paclitaxel.]
[J01FA08, troleandomycin, The metabolism of Paclitaxel can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the neurotoxic activities of Paclitaxel.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Paclitaxel.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belimumab.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Paclitaxel.]
[L02BX03, abiraterone, The metabolism of Paclitaxel can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Paclitaxel can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Paclitaxel can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Paclitaxel can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Paclitaxel.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Paclitaxel.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Paclitaxel can be decreased when combined with Rivaroxaban.]
[B01AC24, ticagrelor, The metabolism of Paclitaxel can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Paclitaxel can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Paclitaxel can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Paclitaxel can be increased when combined with Vinblastine.]
[C04AX07, vincamine, Paclitaxel may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Paclitaxel.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Paclitaxel.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Paclitaxel.]
[A11HA03, vitamin E, The metabolism of Paclitaxel can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Paclitaxel.]
[S01AA13, fusidic acid, The metabolism of Paclitaxel can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Paclitaxel may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Paclitaxel can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Paclitaxel can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Paclitaxel can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Paclitaxel.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Paclitaxel.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Paclitaxel.]
[L01ED01, crizotinib, The metabolism of Paclitaxel can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.]
[R03DC01, zafirlukast, The metabolism of Paclitaxel can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Paclitaxel.]
[N05AE04, ziprasidone, The metabolism of Paclitaxel can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Paclitaxel can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paclitaxel.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Paclitaxel.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Paclitaxel.]
[C07AB03, atenolol, Paclitaxel may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paclitaxel.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Paclitaxel.]
[J02AC03, voriconazole, The metabolism of Paclitaxel can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Paclitaxel may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Paclitaxel.]
[R07AX02, ivacaftor, The metabolism of Paclitaxel can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Paclitaxel can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Paclitaxel.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Paclitaxel.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Paclitaxel.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Paclitaxel.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Paclitaxel.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Paclitaxel.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Paclitaxel.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Paclitaxel can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Paclitaxel can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Paclitaxel.]
[L04AA31, teriflunomide, The metabolism of Paclitaxel can be decreased when combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Paclitaxel.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Paclitaxel.]
[N05CA04, barbital, The metabolism of Paclitaxel can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.]
[J05AE04, nelfinavir, The metabolism of Paclitaxel can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Paclitaxel.]
[C08CA13, lercanidipine, The metabolism of Paclitaxel can be decreased when combined with Lercanidipine.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Paclitaxel.]
[L04AA29, tofacitinib, Paclitaxel may increase the immunosuppressive activities of Tofacitinib.]
[N01AA01, ethyl ether, Paclitaxel may increase the neurotoxic activities of Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Paclitaxel can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The metabolism of Paclitaxel can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Paclitaxel can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Paclitaxel.]
[B01AF02, apixaban, The metabolism of Paclitaxel can be decreased when combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Paclitaxel.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Paclitaxel can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Paclitaxel.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Paclitaxel.]
[N05AD07, benperidol, Paclitaxel may increase the neurotoxic activities of Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, Paclitaxel may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[A06AX06, tegaserod, The metabolism of Paclitaxel can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Paclitaxel can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Paclitaxel.]
[L01EC02, dabrafenib, The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Paclitaxel can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Paclitaxel.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Paclitaxel can be decreased when combined with Riociguat.]
[L03AA14, lipegfilgrastim, Paclitaxel may increase the myelosuppressive activities of Lipegfilgrastim.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[C02KX04, macitentan, Paclitaxel may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Paclitaxel can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Paclitaxel can be decreased when combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Paclitaxel.]
[N03AF04, eslicarbazepine, The metabolism of Paclitaxel can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Paclitaxel can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Acebutolol is combined with Paclitaxel.]
[N05CH03, tasimelteon, The metabolism of Paclitaxel can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Paclitaxel can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Paclitaxel can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Paclitaxel can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Paclitaxel can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Paclitaxel.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Paclitaxel.]
[C02CC01, bethanidine, Paclitaxel may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Paclitaxel can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Paclitaxel can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Paclitaxel.]
[B01AC26, vorapaxar, The metabolism of Paclitaxel can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Paclitaxel.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Paclitaxel.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Paclitaxel can be decreased when combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Paclitaxel can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The metabolism of Paclitaxel can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, Paclitaxel may increase the neurotoxic activities of Acepromazine.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Paclitaxel can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Paclitaxel can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Paclitaxel.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Paclitaxel.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Paclitaxel.]
[N06AX11, mirtazapine, The metabolism of Paclitaxel can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Paclitaxel can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Paclitaxel.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Paclitaxel.]
[J05AP07, daclatasvir, The metabolism of Paclitaxel can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Paclitaxel can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Paclitaxel.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Paclitaxel.]
[J05AP06, asunaprevir, The metabolism of Paclitaxel can be increased when combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Paclitaxel.]
[N05AX16, brexpiprazole, Paclitaxel may increase the neurotoxic activities of Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Paclitaxel.]
[N05AX15, cariprazine, Paclitaxel may increase the neurotoxic activities of Cariprazine.]
[S01EC01, acetazolamide, The metabolism of Paclitaxel can be decreased when combined with Acetazolamide.]
[N05AB07, acetophenazine, Acetophenazine may increase the neurotoxic activities of Paclitaxel.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Paclitaxel can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Paclitaxel.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Paclitaxel can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Paclitaxel.]
[J05AF13, tenofovir alafenamide, The metabolism of Paclitaxel can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Paclitaxel.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Paclitaxel.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Paclitaxel.]
[B01AC27, selexipag, The metabolism of Paclitaxel can be decreased when combined with Selexipag.]
[M04AB05, lesinurad, The metabolism of Paclitaxel can be increased when combined with Lesinurad.]
[L01XA04, satraplatin, The risk or severity of adverse effects can be increased when Satraplatin is combined with Paclitaxel.]
[J05AP10, elbasvir, The metabolism of Paclitaxel can be decreased when combined with Elbasvir.]
[N05CA05, aprobarbital, The metabolism of Paclitaxel can be increased when combined with Aprobarbital.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Paclitaxel.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paclitaxel.]
[N06AA19, amineptin, Paclitaxel may increase the neurotoxic activities of Amineptine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Paclitaxel.]
[N05AX17, pimavanserin, The metabolism of Paclitaxel can be decreased when combined with Pimavanserin.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Paclitaxel.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Bupivacaine.]
[C07AA19, bupranolol, Paclitaxel may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Paclitaxel can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, The metabolism of Paclitaxel can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Paclitaxel.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Paclitaxel.]
[P01BE02, artemether, The metabolism of Paclitaxel can be decreased when combined with Artemether.]
[S01GX07, azelastine, The metabolism of Paclitaxel can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Paclitaxel can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Paclitaxel can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Paclitaxel can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Paclitaxel.]
[N07XX16, deutetrabenazine, The metabolism of Paclitaxel can be decreased when combined with Deutetrabenazine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Paclitaxel.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Paclitaxel can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Paclitaxel.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Paclitaxel.]
[J05AE09, tipranavir, The metabolism of Paclitaxel can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Paclitaxel can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Paclitaxel can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Paclitaxel can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Paclitaxel.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Paclitaxel.]
[L04AC14, sarilumab, The metabolism of Paclitaxel can be increased when combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Paclitaxel.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Paclitaxel can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Paclitaxel.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Paclitaxel.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Paclitaxel.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Paclitaxel.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Paclitaxel.]
[A02BX12, bismuth subnitrate, Paclitaxel may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Paclitaxel.]
[J05AG03, efavirenz, The metabolism of Paclitaxel can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Paclitaxel.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Paclitaxel.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Paclitaxel.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nesiritide.]
[N05AD06, bromperidol, Paclitaxel may increase the neurotoxic activities of Bromperidol.]
[R03BA02, budesonide, The metabolism of Paclitaxel can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Paclitaxel.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Paclitaxel.]
[J05AX18, letermovir, The metabolism of Paclitaxel can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Paclitaxel may increase the neurotoxic activities of Butriptyline.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Paclitaxel.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Capsaicin.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Paclitaxel.]
[L02BB05, apalutamide, The metabolism of Paclitaxel can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Paclitaxel can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Paclitaxel.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Paclitaxel.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Carvedilol is combined with Paclitaxel.]
[B02BX09, fostamatinib, The metabolism of Paclitaxel can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Paclitaxel can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Paclitaxel can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Baricitinib.]
[C07AB08, celiprolol, Paclitaxel may increase the hypotensive activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Paclitaxel can be decreased when combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Paclitaxel can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Paclitaxel can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Paclitaxel can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Paclitaxel can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Paclitaxel can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Paclitaxel.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Chloroprocaine.]
[L01ED05, lorlatinib, The metabolism of Paclitaxel can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Paclitaxel can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Paclitaxel.]
[L01EX13, gilteritinib, The metabolism of Paclitaxel can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Paclitaxel can be decreased when combined with Glasdegib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ravulizumab.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Paclitaxel.]
[B01AC23, cilostazol, The metabolism of Paclitaxel can be decreased when combined with Cilostazol.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The metabolism of Paclitaxel can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Paclitaxel can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Paclitaxel.]
[J01FA09, clarithromycin, The metabolism of Paclitaxel can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Paclitaxel.]
[N05BA09, clobazam, The metabolism of Paclitaxel can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Paclitaxel can be increased when combined with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Paclitaxel can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Paclitaxel can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Paclitaxel can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Paclitaxel can be increased when combined with Alpelisib.]
[J01DC04, cefaclor, Paclitaxel may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L01XX66, selinexor, The excretion of Paclitaxel can be decreased when combined with Selinexor.]
[L02BB06, darolutamide, The excretion of Paclitaxel can be decreased when combined with Darolutamide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Paclitaxel.]
[N05AA06, cyamemazine, Paclitaxel may increase the neurotoxic activities of Cyamemazine.]
[C03BX03, cicletanine, Paclitaxel may increase the hypotensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the neurotoxic activities of Paclitaxel.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Upadacitinib.]
[L01EJ02, fedratinib, The excretion of Paclitaxel can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Paclitaxel.]
[N07XX11, pitolisant, The serum concentration of Paclitaxel can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Paclitaxel can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Paclitaxel can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Paclitaxel can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Paclitaxel.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel.]
[J01DB01, cephalexin, The metabolism of Paclitaxel can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Paclitaxel can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Paclitaxel can be increased when combined with Deflazacort.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Paclitaxel.]
[L01FD01, trastuzumab, The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Paclitaxel.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Paclitaxel.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Paclitaxel.]
[B06AX03, voxelotor, The serum concentration of Paclitaxel can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Paclitaxel can be decreased when it is combined with Cenobamate.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Paclitaxel.]
[L01XX72, tazemetostat, The metabolism of Paclitaxel can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Paclitaxel.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Paclitaxel.]
[C10AX15, bempedoic acid, The excretion of Paclitaxel can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The metabolism of Paclitaxel can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Paclitaxel can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Paclitaxel can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Paclitaxel can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, The metabolism of Paclitaxel can be decreased when combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Paclitaxel can be decreased when combined with Selumetinib.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Paclitaxel.]
[M01AH02, rofecoxib, The metabolism of Paclitaxel can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.]
[C08CA16, clevidipine, The metabolism of Paclitaxel can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Paclitaxel.]
[J01FA13, dirithromycin, The metabolism of Paclitaxel can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Paclitaxel.]
[S03AA08, chloramphenicol, The metabolism of Paclitaxel can be decreased when combined with Chloramphenicol.]
[C02AA06, methoserpidine, Paclitaxel may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Paclitaxel.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Paclitaxel.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Opicapone.]
[D07XB03, fluprednidene, The metabolism of Paclitaxel can be increased when combined with Fluprednidene.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Paclitaxel.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Paclitaxel is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Stepronin.]
[C08CA17, levamlodipine, The metabolism of Paclitaxel can be decreased when combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Paclitaxel can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The excretion of Paclitaxel can be decreased when combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, Paclitaxel may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Paclitaxel can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Paclitaxel.]
[P01BA01, chloroquine, The metabolism of Paclitaxel can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Paclitaxel can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Paclitaxel.]
[R06AB04, chlorpheniramine, The metabolism of Paclitaxel can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Paclitaxel can be increased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, Paclitaxel may increase the neurotoxic activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Paclitaxel.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Paclitaxel.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Paclitaxel can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Paclitaxel can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Paclitaxel.]
[L02BX04, relugolix, The metabolism of Paclitaxel can be decreased when combined with Relugolix.]
[L01FX21, naxitamab, Paclitaxel may increase the neurotoxic activities of Naxitamab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Paclitaxel can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vericiguat.]
[N03AX10, felbamate, The metabolism of Paclitaxel can be increased when combined with Felbamate.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel.]
[G04CB01, finasteride, The metabolism of Paclitaxel can be decreased when combined with Finasteride.]
[R03BA03, flunisolide, The metabolism of Paclitaxel can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Paclitaxel can be increased when combined with Fluocinolone acetonide.]
[S01JA01, fluorescein, Paclitaxel may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[L04AA50, ponesimod, The metabolism of Paclitaxel can be decreased when combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Paclitaxel.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paclitaxel.]
[H04AA02, dasiglucagon, Paclitaxel may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Paclitaxel can be decreased when combined with Cimetidine.]
[L01XX73, sotorasib, The serum concentration of Paclitaxel can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Paclitaxel can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Paclitaxel can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel.]
[N06AB04, citalopram, The metabolism of Paclitaxel can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegcetacoplan.]
[C03DA05, finerenone, The metabolism of Paclitaxel can be decreased when combined with Finerenone.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Paclitaxel can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Paclitaxel can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Paclitaxel can be decreased when it is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Paclitaxel can be decreased when combined with Avacopan.]
[A10BB12, glimepiride, Paclitaxel may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Paclitaxel.]
[N06AX25, St. John's wort extract, The metabolism of Paclitaxel can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Paclitaxel can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The metabolism of Paclitaxel can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Paclitaxel.]
[C10AB01, clofibrate, The metabolism of Paclitaxel can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Paclitaxel can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Paclitaxel can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Paclitaxel.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Paclitaxel.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Paclitaxel.]
[C01EB24, mavacamten, The serum concentration of Paclitaxel can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Paclitaxel can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Paclitaxel may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH06, clothiapine, Paclitaxel may increase the neurotoxic activities of Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Paclitaxel can be increased when it is combined with Linzagolix.]
[A04AA01, ondansetron, The metabolism of Paclitaxel can be decreased when combined with Ondansetron.]
[J05AX31, lenacapavir, The metabolism of Paclitaxel can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Paclitaxel is combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Paclitaxel can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Cocaine.]
[C02KB01, metyrosine, Paclitaxel may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Paclitaxel can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Paclitaxel.]
[A10BX03, nateglinide, The metabolism of Paclitaxel can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Paclitaxel can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Paclitaxel.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Paclitaxel.]
[N02CC05, almotriptan, The metabolism of Paclitaxel can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Paclitaxel can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Paclitaxel.]
[N05BA10, ketazolam, The metabolism of Paclitaxel can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Paclitaxel can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Paclitaxel can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Paclitaxel may increase the hypotensive activities of Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Paclitaxel.]
[S01BA03, cortisone, The metabolism of Paclitaxel can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lofexidine.]
[R06AX13, loratadine, The metabolism of Paclitaxel can be decreased when combined with Loratadine.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Paclitaxel.]
[C08CA11, manidipine, The metabolism of Paclitaxel can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Mebeverine.]
[H02AB15, meprednisone, The metabolism of Paclitaxel can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Paclitaxel can be decreased when combined with Mequitazine.]
[C03DA04, eplerenone, The metabolism of Paclitaxel can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, Paclitaxel may increase the neurotoxic activities of Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Paclitaxel.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Paclitaxel.]
[J01FA03, midecamycin, The metabolism of Paclitaxel can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Paclitaxel can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Paclitaxel.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Paclitaxel.]
[S01XA18, cyclosporine, Paclitaxel may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Paclitaxel.]
[N06BA07, modafinil, The metabolism of Paclitaxel can be increased when combined with Modafinil.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Paclitaxel.]
[C10AA07, rosuvastatin, The metabolism of Paclitaxel can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Paclitaxel can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Paclitaxel.]
[G04BE09, vardenafil, The metabolism of Paclitaxel can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Paclitaxel can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Paclitaxel.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Paclitaxel.]
[G03XA01, danazol, The metabolism of Paclitaxel can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Paclitaxel can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Paclitaxel can be decreased when combined with Daunorubicin.]
[C02CC04, debrisoquin, Paclitaxel may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Paclitaxel.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Paclitaxel can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Paclitaxel.]
[L02BB02, nilutamide, The metabolism of Paclitaxel can be decreased when combined with Nilutamide.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Paclitaxel.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Paclitaxel.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.]
[N06AA01, desipramine, The metabolism of Paclitaxel can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Paclitaxel.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Paclitaxel.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paclitaxel.]
[N03AF02, oxcarbazepine, The metabolism of Paclitaxel can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Paclitaxel can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Paclitaxel can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Paclitaxel can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Paclitaxel can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Paclitaxel can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Paclitaxel can be decreased when combined with Paramethadione.]
[B01AC04, clopidogrel, The metabolism of Paclitaxel can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Paclitaxel can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Diazoxide is combined with Paclitaxel.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Phenol.]
[N06AA08, dibenzepin, Paclitaxel may increase the neurotoxic activities of Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Cinchocaine.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Paclitaxel.]
[S01BC03, diclofenac, The metabolism of Paclitaxel can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Paclitaxel can be increased when combined with Dicloxacillin.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Paclitaxel.]
[C02DG01, pinacidil, Paclitaxel may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, The metabolism of Paclitaxel can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipamperone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Paclitaxel.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Paclitaxel.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Paclitaxel can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Paclitaxel can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Paclitaxel can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Paclitaxel.]
[C01AA05, digoxin, Paclitaxel may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Paclitaxel may increase the hypotensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Paclitaxel may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paclitaxel.]
[C04AE04, dihydroergocristine, The metabolism of Paclitaxel can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Paclitaxel.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Paclitaxel.]
[J05AE08, atazanavir, The metabolism of Paclitaxel can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Paclitaxel can be decreased when combined with Treprostinil.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Paclitaxel can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Paclitaxel can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The metabolism of Paclitaxel can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Paclitaxel.]
[B01AC07, dipyridamole, Paclitaxel may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Paclitaxel.]
[N06AA23, quinupramine, Paclitaxel may increase the neurotoxic activities of Quinupramine.]
[A03FA02, cisapride, The metabolism of Paclitaxel can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Paclitaxel.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Paclitaxel.]
[N05AL04, remoxipride, Remoxipride may increase the neurotoxic activities of Paclitaxel.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Paclitaxel can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Paclitaxel can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Paclitaxel can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Paclitaxel may increase the hypotensive activities of Risperidone.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Paclitaxel.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Paclitaxel.]
[A04AD12, aprepitant, The metabolism of Paclitaxel can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Paclitaxel.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Paclitaxel.]
[J05AE07, fosamprenavir, The metabolism of Paclitaxel can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Paclitaxel can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Paclitaxel can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Paclitaxel can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Paclitaxel.]
[R03AC12, salmeterol, The metabolism of Paclitaxel can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Paclitaxel can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, Paclitaxel may increase the neurotoxic activities of Dosulepin.]
[N06AA12, doxepin, Doxepin may increase the neurotoxic activities of Paclitaxel.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the neurotoxic activities of Paclitaxel.]
[C10AA01, simvastatin, The metabolism of Paclitaxel can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Paclitaxel may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, Paclitaxel may increase the neurotoxic activities of Sultopride.]
[C07AB13, talinolol, Paclitaxel may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The metabolism of Paclitaxel can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Paclitaxel.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Paclitaxel.]
[D01BA02, terbinafine, The metabolism of Paclitaxel can be increased when combined with Terbinafine.]
[N05AB05, thiopropazate, Paclitaxel may increase the neurotoxic activities of Thiopropazate.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Paclitaxel.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Paclitaxel.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Paclitaxel.]
[N03AX11, topiramate, The metabolism of Paclitaxel can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Paclitaxel can be decreased when combined with Torasemide.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Paclitaxel.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Paclitaxel.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Paclitaxel.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Paclitaxel.]
[C02CA06, urapidil, Paclitaxel may increase the hypotensive activities of Urapidil.]
[N05AL06, veralipride, Paclitaxel may increase the neurotoxic activities of Veralipride.]
[L01CA04, vinorelbine, Paclitaxel may increase the neurotoxic activities of Vinorelbine.]
[C08CA12, mepirodipine, The metabolism of Paclitaxel can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Paclitaxel can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Paclitaxel.]
[C09AA15, zofenopril, Paclitaxel may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Paclitaxel.]
[N03AX15, zonisamide, The metabolism of Paclitaxel can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Paclitaxel can be decreased when combined with Zopiclone.]
[N05AX11, zotepine, Paclitaxel may increase the neurotoxic activities of Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Paclitaxel.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Paclitaxel.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Paclitaxel.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Paclitaxel.]
[C01BG01, moricizine, Moricizine may increase the neurotoxic activities of Paclitaxel.]
[N02CA02, ergotamine, The metabolism of Paclitaxel can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Paclitaxel can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The metabolism of Paclitaxel can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, The metabolism of Paclitaxel can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Paclitaxel.]
[J04AK02, ethambutol, The metabolism of Paclitaxel can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The metabolism of Paclitaxel can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Paclitaxel can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Paclitaxel can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Paclitaxel.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Paclitaxel.]
[N05AE03, sertindole, Paclitaxel may increase the neurotoxic activities of Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Paclitaxel.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Paclitaxel.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Paclitaxel.]
[R06AX12, terfenadine, The metabolism of Paclitaxel can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Paclitaxel.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Paclitaxel.]
[C10AA03, pravastatin, Paclitaxel may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Paclitaxel which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Paclitaxel.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Paclitaxel.]
[P02CA03, albendazole, The metabolism of Paclitaxel can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Paclitaxel can be decreased when combined with Felodipine.]
[N02AB03, fentanyl, The metabolism of Paclitaxel can be decreased when combined with Fentanyl.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Paclitaxel.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Paclitaxel.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Paclitaxel.]
[J01CF05, floxacillin, The metabolism of Paclitaxel can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Paclitaxel can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Paclitaxel.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Paclitaxel.]
[D07AC08, fluocinonide, The metabolism of Paclitaxel can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Paclitaxel may increase the neurotoxic activities of Melitracen.]
[H02AB03, fluocortolone, The metabolism of Paclitaxel can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Paclitaxel.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Paclitaxel.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Paclitaxel.]
[L01BC02, fluorouracil, The metabolism of Paclitaxel can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Paclitaxel can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Paclitaxel.]
[N05AB02, fluphenazine, Fluphenazine may increase the neurotoxic activities of Paclitaxel.]
[N05AG01, fluspirilene, Paclitaxel may increase the neurotoxic activities of Fluspirilene.]
[L02BB01, flutamide, The metabolism of Paclitaxel can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Paclitaxel.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Paclitaxel.]
[J05AE10, darunavir, The serum concentration of Paclitaxel can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Paclitaxel.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Paclitaxel.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Paclitaxel.]
[N05AL05, amisulpride, Paclitaxel may increase the neurotoxic activities of Amisulpride.]
[M03AC02, gallamine, Paclitaxel may increase the neurotoxic activities of Gallamine.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Paclitaxel.]
[N03AA04, barbexaclone, The metabolism of Paclitaxel can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Paclitaxel can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Paclitaxel.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Paclitaxel.]
[J05AG04, etravirine, The metabolism of Paclitaxel can be increased when combined with Etravirine.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Paclitaxel.]
[N01AH02, alfentanil, The metabolism of Paclitaxel can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Paclitaxel can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Paclitaxel can be decreased when combined with Glyburide.]
[A10BB07, glipizide, Paclitaxel may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paclitaxel.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Paclitaxel.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Paclitaxel.]
[C02CA04, doxazosin, The metabolism of Paclitaxel can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Paclitaxel.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Paclitaxel.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Paclitaxel.]
[D01BA01, griseofulvin, The metabolism of Paclitaxel can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Paclitaxel may increase the hypotensive activities of Guanethidine.]
[P01BX01, halofantrine, The metabolism of Paclitaxel can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.]
[N05AH04, quetiapine, The metabolism of Paclitaxel can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Paclitaxel.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Paclitaxel.]
[C09CA01, losartan, The metabolism of Paclitaxel can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Paclitaxel.]
[G03DC01, allylestrenol, The metabolism of Paclitaxel can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Paclitaxel.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Paclitaxel.]
[J05AG01, nevirapine, The metabolism of Paclitaxel can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Paclitaxel can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Paclitaxel.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Paclitaxel.]
[C02DB02, hydralazine, The metabolism of Paclitaxel can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Paclitaxel.]
[S02BA01, hydrocortisone, The metabolism of Paclitaxel can be increased when combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Paclitaxel can be increased when combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Paclitaxel.]
[P01BA02, hydroxychloroquine, The metabolism of Paclitaxel can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Paclitaxel may increase the neurotoxic activities of Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Paclitaxel.]
[N05BB01, hydroxyzine, The metabolism of Paclitaxel can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Paclitaxel can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Paclitaxel may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Paclitaxel.]
[R02AX02, ibuprofen, The metabolism of Paclitaxel can be decreased when combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Paclitaxel.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Paclitaxel.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Paclitaxel.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Paclitaxel.]
[N06AA02, imipramine, The metabolism of Paclitaxel can be decreased when combined with Imipramine.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Antilymphocyte immunoglobulin (horse).]
[R03BA09, fluticasone furoate, The metabolism of Paclitaxel can be increased when combined with Fluticasone furoate.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Paclitaxel poliglumex.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Paclitaxel.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Paclitaxel.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Indapamide is combined with Paclitaxel.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Paclitaxel.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Indoramin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Paclitaxel.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paclitaxel.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Paclitaxel.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Paclitaxel can be decreased when combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Paclitaxel can be decreased when combined with Alprazolam.]
[C10AA06, cerivastatin, The metabolism of Paclitaxel can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Paclitaxel.]
[C07AA01, alprenolol, Paclitaxel may increase the hypotensive activities of Alprenolol.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paclitaxel.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Paclitaxel.]
[N06AA13, iprindole, Paclitaxel may increase the neurotoxic activities of Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Paclitaxel.]
[N05AA07, chlorproethazine, Paclitaxel may increase the neurotoxic activities of Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Paclitaxel.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Paclitaxel.]
[J04AC01, isoniazid, The metabolism of Paclitaxel can be decreased when combined with Isoniazid.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Paclitaxel.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Paclitaxel.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Isoxsuprine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Paclitaxel.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Paclitaxel.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Paclitaxel.]
[L04AC07, tocilizumab, The metabolism of Paclitaxel can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Paclitaxel can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Paclitaxel.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Paclitaxel.]
[J02AB02, ketoconazole, The metabolism of Paclitaxel can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Paclitaxel.]
[M02AA10, ketoprofen, The metabolism of Paclitaxel can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Paclitaxel can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Paclitaxel can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rotigotine.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Paclitaxel.]
[C02AA05, deserpidine, Paclitaxel may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Paclitaxel can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Paclitaxel.]
[G03AD01, levonorgestrel, The metabolism of Paclitaxel can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Paclitaxel is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Lidocaine.]
[J01FF02, lincomycin, Paclitaxel may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Paclitaxel can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Paclitaxel.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Paclitaxel.]
[N06AA07, lofepramine, Paclitaxel may increase the neurotoxic activities of Lofepramine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Paclitaxel.]
[A07DA03, loperamide, The metabolism of Paclitaxel can be decreased when combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Paclitaxel can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the neurotoxic activities of Paclitaxel.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Paclitaxel.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Paclitaxel.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Paclitaxel can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Paclitaxel.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Paclitaxel.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Paclitaxel.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Paclitaxel.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Paclitaxel.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Paclitaxel.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Paclitaxel.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Paclitaxel.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Paclitaxel.]
[N02AB02, meperidine, The metabolism of Paclitaxel can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Paclitaxel can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Paclitaxel can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Paclitaxel can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, Mesoridazine may increase the neurotoxic activities of Paclitaxel.]
[N05AX13, paliperidone, The metabolism of Paclitaxel can be decreased when combined with Paliperidone.]
[H01CB03, lanreotide, The metabolism of Paclitaxel can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Paclitaxel can be decreased when combined with Methadone.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Paclitaxel.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Paclitaxel.]
[H03BB02, methimazole, The metabolism of Paclitaxel can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Paclitaxel.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Paclitaxel.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Paclitaxel.]
[N05AA02, methotrimeprazine, Paclitaxel may increase the neurotoxic activities of Methotrimeprazine.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Paclitaxel.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Paclitaxel.]
[V04CG05, methylene blue, The metabolism of Paclitaxel can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Paclitaxel can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Paclitaxel.]
[H02AB04, methylprednisolone, The metabolism of Paclitaxel can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Paclitaxel can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Paclitaxel can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Paclitaxel.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Paclitaxel.]
[P01AB01, metronidazole, The metabolism of Paclitaxel can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Paclitaxel can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Paclitaxel can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Paclitaxel can be decreased when combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Paclitaxel.]
[N05CD08, midazolam, The metabolism of Paclitaxel can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Paclitaxel.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Paclitaxel.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Paclitaxel.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Paclitaxel.]
[J01FA11, miocamycin, The metabolism of Paclitaxel can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Paclitaxel can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Paclitaxel.]
[N05AE02, molindone, Paclitaxel may increase the neurotoxic activities of Molindone.]
[L03AC01, aldesleukin, The metabolism of Paclitaxel can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Paclitaxel can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Paclitaxel can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Paclitaxel can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Paclitaxel can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Paclitaxel can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Paclitaxel.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paclitaxel.]
[N05CA02, amobarbital, The metabolism of Paclitaxel can be increased when combined with Amobarbital.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Raltegravir.]
[P01BA06, amodiaquine, The metabolism of Paclitaxel can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Paclitaxel can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may increase the neurotoxic activities of Paclitaxel.]
[N03AB05, fosphenytoin, The serum concentration of Paclitaxel can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paclitaxel.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Nadolol is combined with Paclitaxel.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Paclitaxel.]
[J01CF06, nafcillin, The metabolism of Paclitaxel can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Paclitaxel can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Paclitaxel.]
[L04AC03, anakinra, The metabolism of Paclitaxel can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Paclitaxel can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Paclitaxel can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Paclitaxel is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Paclitaxel.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Paclitaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Paclitaxel.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Paclitaxel.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Paclitaxel.]
[A10BX02, repaglinide, The metabolism of Paclitaxel can be decreased when combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Paclitaxel.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Paclitaxel.]
[N05AX14, iloperidone, The metabolism of Paclitaxel can be decreased when combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Paclitaxel.]
[N06AX23, desvenlafaxine, The metabolism of Paclitaxel can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Paclitaxel may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Paclitaxel.]
[C10AD02, niacin, The metabolism of Paclitaxel can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Paclitaxel.]
[C08CA04, nicardipine, The metabolism of Paclitaxel can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The metabolism of Paclitaxel can be decreased when combined with Nifedipine.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Paclitaxel.]
[C08CA07, nisoldipine, The metabolism of Paclitaxel can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Paclitaxel can be decreased when combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Paclitaxel.]
[J01XE01, nitrofurantoin, Paclitaxel may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Paclitaxel can be decreased when combined with Zaleplon.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Paclitaxel.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Paclitaxel.]
[G03DC02, norethindrone, The metabolism of Paclitaxel can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Paclitaxel.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Paclitaxel.]
[C02KX01, bosentan, The metabolism of Paclitaxel can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Paclitaxel.]
[R05DA07, noscapine, The metabolism of Paclitaxel can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Paclitaxel.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Paclitaxel.]
[G01AA01, nystatin, The excretion of Paclitaxel can be decreased when combined with Nystatin.]
[H01CB02, octreotide, The serum concentration of Paclitaxel can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, Paclitaxel may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[J01FA05, oleandomycin, The metabolism of Paclitaxel can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Paclitaxel can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Paclitaxel can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Paclitaxel may increase the neurotoxic activities of Opipramol.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Paclitaxel.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Paclitaxel.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Paclitaxel.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Paclitaxel.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Paclitaxel can be decreased when combined with Oxycodone.]
[N05AE01, oxypertine, Paclitaxel may increase the neurotoxic activities of Oxypertine.]
[N05AH05, asenapine, Paclitaxel may increase the neurotoxic activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Paclitaxel.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Paclitaxel.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.]
[H02AB05, paramethasone, The metabolism of Paclitaxel can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Paclitaxel.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Penbutolol.]
[N05AG03, penfluridol, Paclitaxel may increase the neurotoxic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Paclitaxel.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paclitaxel.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paclitaxel.]
[N05CA01, pentobarbital, The metabolism of Paclitaxel can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Paclitaxel.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Paclitaxel.]
[N05AB10, perazine, Paclitaxel may increase the neurotoxic activities of Perazine.]
[N05AB03, perphenazine, Perphenazine may increase the neurotoxic activities of Paclitaxel.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Paclitaxel.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Paclitaxel.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Paclitaxel.]
[N03AA02, phenobarbital, The metabolism of Paclitaxel can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Paclitaxel.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Paclitaxel.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Paclitaxel.]
[M02AA01, phenylbutazone, The metabolism of Paclitaxel can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The serum concentration of Paclitaxel can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Paclitaxel can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Paclitaxel.]
[C08CX01, mibefradil, The metabolism of Paclitaxel can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Paclitaxel.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Paclitaxel.]
[C10AA05, atorvastatin, The metabolism of Paclitaxel can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Paclitaxel can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, Paclitaxel may increase the neurotoxic activities of Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Paclitaxel.]
[S01BC06, piroxicam, The metabolism of Paclitaxel can be decreased when combined with Piroxicam.]
[J05AG02, delavirdine, The metabolism of Paclitaxel can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Paclitaxel can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Paclitaxel.]
[D05AX05, tazarotene, The metabolism of Paclitaxel can be decreased when combined with Tazarotene.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Paclitaxel.]
[A10BG02, rosiglitazone, The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Paclitaxel can be decreased when combined with Anastrozole.]
[L04AC08, canakinumab, The metabolism of Paclitaxel can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Paclitaxel may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Paclitaxel.]
[J05AE03, ritonavir, The serum concentration of Paclitaxel can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Paclitaxel can be decreased when combined with Saxagliptin.]
[C10AA08, pitavastatin, The metabolism of Paclitaxel can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, Paclitaxel may increase the hypotensive activities of Practolol.]
[P02BA01, praziquantel, The metabolism of Paclitaxel can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Paclitaxel.]
[S03BA02, prednisolone, The metabolism of Paclitaxel can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Paclitaxel.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Paclitaxel can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Paclitaxel can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Paclitaxel can be increased when combined with Probenecid.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Paclitaxel.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Paclitaxel.]
[C10AB05, fenofibrate, The metabolism of Paclitaxel can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the neurotoxic activities of Paclitaxel.]
[G03DA04, progesterone, The metabolism of Paclitaxel can be decreased when combined with Progesterone.]
[N05AA03, promazine, Promazine may increase the neurotoxic activities of Paclitaxel.]
[R06AD02, promethazine, Promethazine may increase the neurotoxic activities of Paclitaxel.]
[N05AC01, periciazine, Paclitaxel may increase the neurotoxic activities of Periciazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Paclitaxel.]
[N01AX10, propofol, The metabolism of Paclitaxel can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Paclitaxel can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Paclitaxel can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Paclitaxel.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Paclitaxel.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Paclitaxel can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the neurotoxic activities of Paclitaxel.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Paclitaxel.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Paclitaxel.]
[P01BD01, pyrimethamine, The metabolism of Paclitaxel can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Paclitaxel can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Paclitaxel.]
[P01BC01, quinine, The metabolism of Paclitaxel can be increased when combined with Quinine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Paclitaxel.]
[C02AA01, rescinnamine, Paclitaxel may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The metabolism of Paclitaxel can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Paclitaxel can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Paclitaxel can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Paclitaxel.]
[N05CA06, secobarbital, The metabolism of Paclitaxel can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Paclitaxel can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.]
[H01CB01, somatostatin, The metabolism of Paclitaxel can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Paclitaxel.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Paclitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.]
[C03DA01, spironolactone, The metabolism of Paclitaxel can be decreased when combined with Spironolactone.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Paclitaxel.]
[H02CA04, levoketoconazole, The metabolism of Paclitaxel can be decreased when combined with Levoketoconazole.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paclitaxel.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
